2020 Life Science Venture Capital Funding Roundup for Q1/Q2 in the BioHealth Capital Region
BioHealth Companies raised more than $178M in the first half of 2020
June 9, 2020
This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.
No one has escaped the reach of COVID-19 in the BHCR, the rest of the U.S., or around the globe. While this industry continues to be uniquely positioned to weather a storm like this, many were still impacted via delayed clinical trials and having to adjust to near 100% remote work for non-bench role employees. Some areas like Travel Medicine have been hit hard, as most are canceling their 2020 trips. Sadly, even when daily life resembles a new normal, Travel Medicine is likely to have a longer recovery as many organizations have adapted to virtual meetings that will potentially reduce future travel significantly.
The regional life science ecosystem was prepared and pivoted rapidly to not only ensure continued operations, but also to redirect resources, talent and technologies to creating testing, developing COVID-19 therapies and progressing SARS-CoV-2 vaccine candidates.
The BHCR life science community has been remarkably resilient and innovative during this time, for certain, despite myriad challenges caused by COVID-19 across VC funding, the supply chain, and clinical trials, to name just a few.
Despite all of the tumult and turmoil, VC funding deals are still getting done in the BHCR, though perhaps currently on a slightly slower pace and scale. We’ll see what the second half holds on the VC funding front, but with signs of a slow, steady, and careful reopening afoot in the region, it’s possible that funding deals will pick back up in the latter half of 2020.
With that, let’s take a look at funding deals that were announced in the BHCR in Q1/Q2 of 2020, the year of the pandemic.
Immunomic Therapeutics Closes $61.3M Financing Round
Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising projections by over $11M. The Korean investment group HLB Co., LTD led the financing round, which is just the latest accomplishment for the clinical-stage biotechnology company that launched in 2006.
Read more about CEO Bill Hearl’s plans for ITI in our recent BioBuzz story, “Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO.”
LifeSprout Closes $28.5M Series A
LifeSprout, a privately-held regenerative medicine company located in Baltimore, Maryland, recently announced the closing of a $28.5M Series A financing round, marking a significant milestone in its history. The round was led by Redmile Group, LLC, with new institutional investors Nexus Management, LP, Emerald Development Managers, LP, and Baltimore’s Abell Foundation joining the investment group.
You can read more about LifeSprout’s story and plans in our recent featured story, “Baltimore, Maryland’s LifeSprout Closes $28.5M Series-A, Looks Toward the Future.”
IBT Vaccines Secures $3.9M in Funding to Advance Staphylococcus aureus Vaccine
Integrated Biotherapeutics’ subsidiary IBT Vaccines, which is located in Rockville, Maryland received $3.9M in funding as part of a larger $48M investment in eight companies by Novo Holding’s REPAIR Impact Fund.
The funding will be used to advance its “…advance the development of the IBT-V02 vaccine for Staphylococcus aureus induced recurrent skin and skin structure infections (SSSI),” according to the company’s press release in early January 2020. At the time of the announcement, the vaccine was in the late clinical development stage and is potentially a first-to-market, multivalent vaccine for antibiotic resistant Staphylococcus aureus.
Vigene Biosciences Secures Institutional Investment
Vigene Biosciences, which just recently opened its new headquarters in Rockville, Maryland, announced in late March that it had secured institutional investment from Signet Healthcare Partners (“Signet”), a New York-based growth equity firm specializing in healthcare investments.
Vigene is a leading provider of viral vector products and services used in gene therapy. According to Washington Business Journal reporting, the round was close to $3M.
We wrote about Vigene’s new HQ grand opening and its remarkable relationships with the families it serves. You can read “Maryland Biotech Opens New Gene Therapy Contract Manufacturing Facility To Support Rapid Growth” to learn more.
Pathotrak Closes $1.2M Seed Round
College Park, Maryland’s Pathotrak announced it had closed a seed round of $1.2M in mid-May 2020. The company has developed a rapid food test for salmonella and E. coli in food. The company’s new test has the potential to cut down food safety test result turnaround times by nearly one full day, which could have a significant positive financial impact on the food industry while improving food safety for companies and consumers.
The Maryland Momentum Fund contributed $150K, the Dingman Angels, which is a program within the Robert H. Smith School of Business at the University of Maryland, invested $310K, and a global life sciences company with a food safety division also invested in pathOtrack.
You can read more here about Pathtrack’s novel test and the company in a story BioBuzz recently published.
ARMR Systems Raises $750K in Seed Funding
ARMR Systems, a Maryland BioPark-affiliated startup, received seed money from local funding sources to support its hemorrhagic control systems designed to increase the survivability of battlefield trauma when advanced medical support is not immediately available.
The seed funding included a $350,000 joint investment from the University of Maryland, Baltimore, and the Maryland Momentum Fund and also included funding from the Tamiami Angel Fund.
ARMR Systems was featured in the BioBuzz story, “Baltimore’s Top 10 BioHealth Startup CEOs.”
There were several large HealthTech investments in this first half of the year that include:
b.well Connected Health Lands $16M Series A
Timonium, Maryland’s b.well Connected Health secured $16M in Series A financing to back its patient-facing health management tool. The round was led by UnityPoint Health Ventures, with participation from ThedaCare and Well Ventures.
B.well’s management tool integrates “data, insights, and partners into a single customized solution that helps people take control of their healthcare experience,” according to the company’s website. The company is located at The Grid, which is located at the Lion Brothers Building one block south of the University of Maryland Biopark. The company will use the Series A funding to scale as it enters a growth and hiring phase.
Aledade Closes Series C Round
Bethesda, Maryland’s Aledade, a data analytics and healthcare practice workflow company, closed a $64M Series C round led by OMERS Growth Equity. California Medical Association, Echo Health Ventures, and Meritech Capital and GV also contributed to the round. Aledade has created a network of approximately 550 doctor-led Accountable Care Organizations (AOC) that utilize an outcome-based rather than a fee for service business model. The company plans to use the Series C funding to expand its U.S. footprint and AOC practice network.
In the first half of 2020, the resilient nature of the BioHealth Capital Region has been on full display, yet a sobering reality exists: we still don’t have a COVID-19 vaccine. And while many companies around the world and region work day and night to create one, the region must remain diligent and smart in how it continues to weather this storm. The second half of 2020 will be interesting to watch, as the region slowly and carefully reopens to a new COVID-19 normal.
If the transition to the post COVID-19 environment goes well, will VC firms come off the sidelines in droves, releasing a flood of new funding? Will companies move forward with M&A that’s been held close and delayed? Will a BioHealth Capital Region life science company be the first to get COVID-19 vaccine approved and manufactured? It’s difficult to answer any of these questions, but it is certain that Q3/Q4 of 2020 will be fascinating to watch.
Latest posts by Steven Surdez (see all)
- BioHealth Capital Fund Created to Help Emerging Companies Close Early Stage Capital Gap - August 11, 2020
- Intellectual Property Law Firm McBee, Moore & Vanik IP, LLC Earns Two National Institutes of Health Ten Year Contracts - August 11, 2020
- Kite Seeking to Hire Cell Therapy Talent Ahead of Opening Its New Advanced Biomanufacturing Facility in Frederick, Maryland - August 7, 2020